The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
Open accessAbstract
Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of the mixed lineage leukemia (MLL) gene, drug resistance, and a poor treatment outcome. Therefore, novel therapeutic strategies are needed to improve prognosis. Recently, we showed that FLT3 is highly expressed in MLL rearranged ALL (MLL). Here we demonstrate FLT3 expression in infants with MLL (n = 41) to be significantly higher compared to both infant (n = 8; P < .001) and noninfant patients with ALL (n = 23; P = .001) carrying germline MLL genes. Furthermore, leukemic cells from infants with MLL were significantly more sensitive to the Fms-like tyrosine kinase 3 (FLT3) inhibitor PKC412 (N-benzoyl staurosporine) than noninfant ALL cells, and at least as sensitive as internal tandem duplication-positive (ITD+) AML cells. Surprisingly, activation loop mutations only occurred in about 3% (1 of 36) of the cases and no FLT3/ITDs were observed. However, measuring FLT3 phosphorylation in infants with MLL expressing varying levels of wild-type FLT3 revealed that high-level FLT3 expression is associated with ligand-independent FLT3 activation. This suggests that infant MLL cells displaying activated FLT3 as a result of overexpression can be targeted by FLT3 inhibitors such as PKC412. However, at concentrations of PKC412 minimally required to fully inhibit FLT3 phosphorylation, the cytotoxic effects were only fractional. Thus, PKC412-induced apoptosis in infant MLL cells is unlikely to be a consequence of FLT3 inhibition alone but may involve inhibition of multiple other kinases by this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Cited by
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 405
Hollink, I. H. I. M., van den Heuvel-Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Pratcorona, M., Abbas, S., Kuipers, J. E., van Galen, J. F., Beverloo, H. B., Sonneveld, E., Kaspers, G.-J. J. L., et al. (2011) · Blood · doi:10.1182/blood-2011-04-346643 · Cited by 334
The molecular biology of mixed lineage leukemia
Slany, R. K. (2009) · Haematologica · doi:10.3324/haematol.2008.002436 · Cited by 321
Pieters, R., De Lorenzo, P., Ancliffe, P., Aversa, L. A., Brethon, B., Biondi, A., Campbell, M., Escherich, G., Ferster, A., Gardner, R. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00261 · Cited by 297
Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia
Wei, J., Wunderlich, M., Fox, C., Alvarez, S., Cigudosa, J. C., Wilhelm, J. S., Zheng, Y., Cancelas, J. A., Gu, Y., Jansen, M., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.020 · Cited by 284
Metadata
- Authors
- Stam, R. W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-10-01
- Volume
- 106
- Issue
- 7
- Pages
- 2484-2490
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2145641334
- Cited by
- 185
- References
- 1
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/blood-2004-09-3667
- The paper
- Stam, R. W. (2005). Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood-2004-09-3667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.